Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,925.80 | 5.50 | -0.06% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,751.36 | 225.43 | -0.87% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,171.44 | 665.11 | -1.31% |
| NZX 50 Index | 13,374.21 | 32.70 | -0.24% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,637.00 | 6.90 | -0.08% |
| SSE Composite Index | 3,876.84 | 12.51 | -0.32% |